An update on allergen immunotherapy and asthma

Area of Science:

• Allergy and Immunology
• Respiratory Medicine

Background:

• Allergen-specific immunotherapy (AIT) is recognized for its efficacy in managing combined allergic rhinitis and asthma.
• Previous research indicated AIT improves clinical outcomes and reduces bronchial hyperresponsiveness.
• Long-term benefits include preventing new sensitizations and the progression of allergic rhinitis to asthma.

Purpose of the Study:

• To review recent literature up to July 2013 on the effects of allergen-specific immunotherapy (AIT) on asthma.
• To assess the impact of AIT on asthma control, symptoms, and medication use.
• To evaluate the potential disease-modifying effects of AIT in asthma management.

Main Methods:

• Literature review of studies published up to July 2013.
• Analysis of findings from observational studies and small open trials.
• Inclusion of meta-analyses supporting clinical benefits in asthma.

Main Results:

• Recent studies confirm AIT improves asthma control, symptoms, and medication usage, with some steroid-sparing effects.
• Meta-analyses support the clinical benefits of AIT for both adult and pediatric asthma.
• Lung function changes were inconsistent in some trials, and few studies were specifically designed for asthma endpoints.

Conclusions:

• Evidence suggests AIT can favorably affect asthma, particularly in patients with allergic rhinitis.
• Sublingual AIT is more extensively studied in children and is better tolerated than injective AIT.
• Further large-scale trials are needed to confirm efficacy, especially given AIT's potential disease-modifying effects compared to standard pharmacotherapy.